blastoids let – In Vienna and beyond, stem-cell embryo models called blastoids are finally letting researchers observe implantation—an early moment in pregnancy that usually stays hidden. By pairing blastoids with lab-made versions of the uterine lining, teams report implanta
Inside a lab in Vienna, cells form a hollow sphere. It resembles an early human embryo closely enough to mislead the eye—but it never began with an egg and sperm. This blastoid was created entirely in the lab. and for researchers trying to understand why early pregnancies fail. that distinction feels like more than technical progress. It’s a crack in the black box.
The earliest days of pregnancy have long been difficult to study because scientists can’t peer inside the uterus during pregnancy. That means so much remains guesswork when embryos need to do the hardest part of their journey: implant. In humans, implantation happens around a week after fertilisation. But it often goes wrong. Only around a third of embryos successfully implant into the uterus, while 60 per cent of IVF embryo transfers fail.
In the five years since early human embryo models known as blastoids were first created in several labs—including the one in Vienna—researchers have advanced quickly. Blastoids let scientists recreate early pregnancy in a dish and then “poke it. perturb it and see how the system copes”. as Peter Rugg-Gunn. a developmental biologist at the University of Cambridge. puts it. The promise is direct: improving IVF and treatments for serious conditions that occur during pregnancy. The catch comes later. once experiments can be sustained longer and the field starts asking the question it can’t avoid anymore—how far is too far?.
What implantation looks like when it’s no longer invisible
After fertilisation. the embryo begins dividing rapidly to form a ball of cells that becomes a blastocyst. To continue developing, it must attach to the uterus. In humans, this implantation step happens about a week after fertilisation, and it is the moment many embryos fail.
Scientists have previously studied mice. where pregnancies differ predictably from humans. and they’ve looked at human embryos via surgical removal in hysterectomies or material expelled in miscarriages—snapshots rather than a continuous view. There has been no way to watch human embryo growth or see the precise moment an embryo embeds into the uterus.
That changed in 2021. when several research teams. including one led by Nicolas Rivron—a stem cell biologist and founder of the lab at the Institute of Molecular Biotechnology in Vienna—successfully created blastoids from human stem cells. Researchers learned how to develop human pluripotent stem cells with early embryonic potential to create many other types of cell. When placed in the right environment. these cells organised themselves into embryo models—a major breakthrough and the platform for work that followed.
This year, the field’s most tangible leap came from two studies that moved implantation into a dish.
In one. Rugg-Gunn and his team built a three-dimensional model of the endometrium—the uterine lining—from biopsy samples taken from healthy women. and they also developed blastoids so that the embryo and uterine lining finally met. Within three days, more than 80 per cent of the blastoids successfully implanted into the artificial endometrium.
In another study. across the ocean. Jun Wu at the University of Texas Southwestern Medical Center and his colleagues created “endometrioids”. postage stamp-sized chips that nourished a bioengineered endometrium model made from donated tissue samples. When blastoids were added, about 60 per cent implanted. But when the donated tissue came from people who had undergone several failed rounds of IVF. the implantation rate fell to 20 per cent.
From watching implantation to changing outcomes
Researchers didn’t stop at seeing implantation. They tested whether they could intervene.
In the Texas work. scientists screened more than 1000 different drugs—each already approved by the US Food and Drug Administration for a variety of conditions—to see if any improved implantation. The screen turned up a handful that successfully increased implantation rates by up to 60 per cent. But the drugs only worked for some samples. The team is now screening for a common drug that works for most people.
This push toward practical use is meeting a reality IVF patients already know too well: one cycle is both physically and emotionally exhausting. On average, eight eggs are extracted per cycle, and 70 to 80 per cent are successfully fertilised. When embryos are transferred into the uterus. typically one at a time. around 35 to 40 per cent develop into pregnancy. though those numbers vary at each step.
Christina Fadler, founder of Austrian fertility advocacy group Die Fruchtbar, knows the strain personally. “The emotional strain is extremely high,” she says. Her sense of depression increased with each negative test result, she says. Costs add pressure too. While some people have costs covered—such as through the National Health Service in the UK or health insurance—others pay £8000 per cycle in the UK or up to $30. 000 in the US.
For Fadler, the attraction is straightforward: if researchers can identify what goes wrong during implantation, fewer people may be asked to endure repeated cycles without clarity. “We are aiming for a 100 per cent own healthy baby rate,” she says.
One of the first practical tools to emerge from the embryo-and-endometrium approach is a test in Texas. Simbryo Technologies developed a test that predicts the chance that the next embryo transfer will be successful. The company creates endometrium models grown from clients’ tissue samples and tests whether blastoids can embed. Aryeh Warmflash. a bioscientist at Rice University in Texas and chief science officer at the company. says the result is meant to clarify where the failure is likely to be. “When things go wrong, we know the problem is on the endometrial side, not the embryo side,” he says.
Fadler is wary of profiteering. but she says these tests could still matter because patients lack even a clear map of where implantation fails. “We still don’t even know what can go wrong during implantation – it’s all such a black box. ” she says. “Everything that’s researched and every bit of additional knowledge generated is important and beneficial for patients in the long run.”.
If the endometrium is only one side of the equation, other teams are working on the embryo side. Dawn-bio, a start-up co-founded by Rivron, wants to improve IVF by optimising embryo growth conditions before transfer into the uterus. Only 20 per cent of fertilised eggs develop sufficiently in time to be transferred. “We’re not giving the embryos what they need,” says Peter Greiner, the company’s chief executive. “Fundamentally. in terms of what is in the medium for growing embryos. nothing new has happened [since the first IVF baby was born] because we don’t know what human embryos need and we can’t do experiments on human embryos.”.
Dawn-bio identified 150 human metabolites it believes are valuable but aren’t currently used when cultivating embryos for IVF. Testing on both blastoids and donated embryos identified seven metabolites that improved embryo quality—quality determined by markers such as symmetry and the number of cells—by day five of development. Greiner calls blastoids a turning point for the field. “Blastoids made a tectonic shift possible for the field of IVF,” he says. “We are aiming for a 100 per cent own healthy baby rate: that 100 per cent of the people who want to have a baby can have their own. healthy baby.”.
A pause in development—and the cells that send signals
Once researchers can watch implantation outside the uterus, surprises start to show up.
At the University of Cambridge. Rugg-Gunn and his team made blastoids express a fluorescent protein so they glowed as they became implanted in endometrial models. The visual evidence revealed that shortly after burrowing into the artificial uterus. the embryo models sent out cells into the endometrium. “We don’t know what these cells are. But now that we can see them, we can study them,” Rugg-Gunn says. The cells may help to anchor the embryo, or they could create communication signals between the embryo and the endometrium. Rugg-Gunn suspects early communication is crucial for implantation and that. when it goes awry. it may be tied to some miscarriages.
Another team found a different kind of control mechanism. Heidar Heidari Khoei. a stem cell biology researcher at the Institute of Molecular Biotechnology. uncovered a “pause button” in human blastoids. It’s likely connected to a mammal trait in which embryo development can slow for weeks before implantation. only resuming when the chances of survival improve. Khoei pushed the pause button in human blastoids by blocking specific signalling pathways, before restarting development by reactivating those pathways.
Anna Osnato. a stem cell biology researcher at Rivron’s lab. is using gene editing to understand what enables implantation to proceed smoothly. Osnato wants to determine which genes allow implantation and influence how the embryo burrows to the right depth. Recently, she identified genes connected with the embryonic cell layer that sticks to the uterus. When those genes were removed, blastoids attached much less frequently.
The same moment that determines implantation may also matter later. Preventing later problems such as pre-eclampsia—affecting 5 to 8 per cent of pregnancies and associated with high blood pressure. organ failure. strokes and seizures—could depend on understanding early implantation. There is growing evidence the issue begins in implantation, when the placenta starts to develop. Rugg-Gunn believes research could lead scientists to identify biomarkers that point to increased risk.
Limits—and the sharp ethical line the field is trying not to cross
Blastoids aren’t only helping scientists at the start. The field is now building models for later stages than the blastocyst. Jacob Hanna at the Weizmann Institute of Science in Israel has published research on stem cell-based embryo models equivalent to embryos 14 days after fertilisation. He says he can grow embryo models to the equivalent of 21 days post-fertilisation and that scientists want to push further.
That possibility is where tension turns ethical.
In theory. it could one day be possible to create a blastoid that develops into a human if implanted in a uterus. In practice, that’s currently impossible. Even mouse and monkey blastoids fail to develop for long when implanted in animal uteruses. Scientists can’t test this line: the guidelines of the International Society for Stem Cell Research (ISSCR) and national frameworks such as the UK Code of Practice forbid inserting a human embryo model into a uterus.
When it comes to human embryos, strict regulations govern how long they can develop in the lab. The UK and Australia allow 14 days of development. while there’s a complete ban on embryo research in countries such as Germany and Austria. But embryo models tend not to fall under those regulations, and there are few clear limits. ISSCR guidance says embryo model research must be justified and have defined endpoints.
Several bioethicists argue that many ethical issues around human embryos don’t apply in the same way because embryo models currently can’t develop into humans. Tsutomu Sawai. a bioethicist at Hiroshima University in Japan. says Japan’s Cabinet Office on Bioethics is “very sceptical of the potentiality to be humans when it comes to stem cell-based embryo models.” Others argue later-stage embryo models could offer benefits. Wu envisions developing embryo models equivalent to a 3-week-old embryo—when the first organs begin to form—so that seed cells for organs could be extracted for improved mini-organs (organoids) or bioprinting to construct living tissue models.
Hanna points to blood stem cells. “A 30-day-old human embryo has the best transplantable blood stem cells in the liver,” he says. But stem cell transplants require a tissue-type match, which is currently unfeasible for patients to find in human embryo sources. Embryo models could be built from a patient’s own stem cells. There is currently no limit on how long embryo models in Israel are allowed to develop. Through his company. Renewal Bio. Hanna says he wants to grow embryo models to 70 days. at which point ovaries form. and use the eggs inside for IVF treatments—allowing people without eggs. or without good-quality eggs. to generate new ones using their stem cells.
Rivron rejects the idea that the field should build near-complete structures just to discard most of them. “It is not going to be acceptable to generate near-complete structures to use a small part of it and discard the rest. ” Rivron says. Hanna acknowledges the moral questions, arguing that the benefit could matter. “But the benefit in the scenario given is an infertile woman who needs her eggs. and this is a way to give [them] to her. Or a patient with leukaemia who is about to die because he cannot find a [blood stem cell] donor. ” he says. “Ethics is not just abstract.”.
Emma Cave. professor of healthcare law at Durham University in the UK and chair of the Nuffield Council on Bioethics review of embryo models. argues that any day 30 or day 70 models are likely to be incomplete. The focus would then shift to developing one or two embryonic tissues rather than the whole embryo. Those models. Cave says. are akin to adult stem cell-based organoids and should have similar ethical oversight focusing on purpose rather than a blanket cutoff point. Cave also warns that if later-stage models begin to resemble human embryos more closely. that could raise concerns about sentience and the ability to feel pain. “Such work is currently impossible. ” she says. but she also says research shouldn’t be approved if it crosses those boundaries. The level of developmental sophistication matters even if a model lacks the ability for consciousness. and limits would need to be carefully assigned.
One step is even more contested: human ectogenesis. growing an embryo or embryo model entirely outside the uterus until fully developed. Wu expects ectogenesis to happen for mice embryo models within the next five years. but says human ectogenesis isn’t yet conceivable. He compares the situation to ambition outpacing reality: “It’s like we haven’t even landed on Mars. but are already talking about going to another galaxy. ” Wu says.
Human ectogenesis research is prohibited by the ISSCR. Rivron agrees with that decision. saying scientists would inevitably need to first create highly advanced fetuses outside the uterus that wouldn’t survive. “I think it’s ethically unacceptable,” he says. Dawn-bio has already been approached by billionaires hoping to fund work on ectogenesis, and the company has turned them away.
Even with those limits, embryo models have already changed the work of fertility science. Over the next five to 10 years. Wu expects to “fill most of the gaps of our early human development”. dramatically advancing the success rates of IVF. And by studying pregnancy outside the uterus. scientists are speeding up the pace of discovery—while the field continues to measure where the real ethical boundaries should be.
All the while, the most immediate transformation is plain: the moment implantation can be watched, tested, and nudged—no uterus required.
blastoids stem cell embryo models implantation IVF endometrium endometrioids pre-eclampsia embryo ethics ISSCR Vienna